Immunovant Historical Cash Flow

Stocks . USA . 
Stock . Immunovant
IMVT Stock  USD 23.78  0.90  3.65%   
Analysis of Immunovant cash flow over time is an excellent tool to project Immunovant future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Cashflows From Financing Activities of 4.3 M or Depreciation of 395.9 K as it is a great indicator of Immunovant ability to facilitate future growth, repay debt on time or pay out dividends.
   Cash Flow   Balance Sheet   Income Statement
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Immunovant latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immunovant is a good buy for the upcoming year.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunovant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.
For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.

About Immunovant Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Immunovant balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Immunovant's non-liquid assets can be easily converted into cash.
Balance Sheet
Statement
Details
Profit & Loss
Statement
Details
Financial
Indicators
Details
Valuation
Indicators
Details

Immunovant Cash Flow Chart

At this time, Immunovant's Depreciation is comparatively stable compared to the past year. Change To Operating Activities is likely to gain to about 12.8 M in 2025, despite the fact that Free Cash Flow is likely to grow to (357.8 M).
Stock Based Compensation  Change To Netincome  Sale Purchase Of Stock  End Period Cash Flow  
Add Fundamental

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.
Most accounts from Immunovant's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Immunovant current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunovant. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.
For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.At this time, Immunovant's Depreciation is comparatively stable compared to the past year. Change To Operating Activities is likely to gain to about 12.8 M in 2025, despite the fact that Free Cash Flow is likely to grow to (357.8 M).

Immunovant cash flow statement Correlations

Change In Cash
Net Borrowings
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Depreciation
Other Non Cash Items
Capital Expenditures
Change To Operating Activities
Net Income
Change To Netincome
Change To Liabilities
Sale Purchase Of Stock
Change To Account Receivables
End Period Cash Flow
Change To Inventory
Investments
Begin Period Cash Flow
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change Receivables
Change In Cash
-0.430.370.040.40.14-0.340.390.2-0.170.270.120.580.060.50.47-0.230.12-0.08-0.040.04
Net Borrowings
-0.43-0.920.580.26-0.820.71-0.65-0.90.39-0.96-0.05-0.52-0.7-0.95-0.970.79-0.890.840.71-0.74
Stock Based Compensation
0.37-0.92-0.67-0.310.86-0.690.830.94-0.630.95-0.020.270.670.980.95-0.830.97-0.91-0.790.81
Free Cash Flow
0.040.58-0.670.73-0.90.28-0.58-0.750.51-0.710.350.22-0.53-0.65-0.520.9-0.740.790.8-0.85
Change In Working Capital
0.40.26-0.310.73-0.620.26-0.27-0.380.24-0.350.770.36-0.64-0.26-0.210.56-0.460.550.72-0.73
Depreciation
0.14-0.820.86-0.9-0.62-0.650.640.92-0.410.91-0.270.010.70.860.75-0.980.9-0.93-0.870.93
Other Non Cash Items
-0.340.71-0.690.280.26-0.65-0.44-0.650.03-0.710.17-0.33-0.65-0.72-0.680.63-0.650.620.53-0.57
Capital Expenditures
0.39-0.650.83-0.58-0.270.64-0.440.64-0.880.65-0.050.180.430.810.78-0.670.78-0.63-0.570.58
Change To Operating Activities
0.2-0.90.94-0.75-0.380.92-0.650.64-0.440.99-0.020.170.720.920.86-0.870.95-0.95-0.810.86
Net Income
-0.170.39-0.630.510.24-0.410.03-0.88-0.44-0.410.060.05-0.26-0.56-0.550.4-0.610.490.49-0.46
Change To Netincome
0.27-0.960.95-0.71-0.350.91-0.710.650.99-0.410.010.30.710.950.91-0.870.95-0.93-0.790.83
Change To Liabilities
0.12-0.05-0.020.350.77-0.270.17-0.05-0.020.060.010.46-0.45-0.010.080.21-0.050.240.54-0.49
Sale Purchase Of Stock
0.58-0.520.270.220.360.01-0.330.180.170.050.30.460.210.360.54-0.080.150.020.15-0.14
Change To Account Receivables
0.06-0.70.67-0.53-0.640.7-0.650.430.72-0.260.71-0.450.210.650.67-0.620.7-0.72-0.770.77
End Period Cash Flow
0.5-0.950.98-0.65-0.260.86-0.720.810.92-0.560.95-0.010.360.650.96-0.850.92-0.86-0.740.78
Change To Inventory
0.47-0.970.95-0.52-0.210.75-0.680.780.86-0.550.910.080.540.670.96-0.730.89-0.8-0.670.69
Investments
-0.230.79-0.830.90.56-0.980.63-0.67-0.870.4-0.870.21-0.08-0.62-0.85-0.73-0.840.830.76-0.84
Begin Period Cash Flow
0.12-0.890.97-0.74-0.460.9-0.650.780.95-0.610.95-0.050.150.70.920.89-0.84-0.94-0.820.86
Cash And Cash Equivalents Changes
-0.080.84-0.910.790.55-0.930.62-0.63-0.950.49-0.930.240.02-0.72-0.86-0.80.83-0.940.94-0.96
Cash Flows Other Operating
-0.040.71-0.790.80.72-0.870.53-0.57-0.810.49-0.790.540.15-0.77-0.74-0.670.76-0.820.94-0.99
Change Receivables
0.04-0.740.81-0.85-0.730.93-0.570.580.86-0.460.83-0.49-0.140.770.780.69-0.840.86-0.96-0.99
Click cells to compare fundamentals

Immunovant Account Relationship Matchups

High Positive Relationship

Change To Netincome
+ 0.99
Change To Operating Activities
End Period Cash Flow
+ 0.98
Stock Based Compensation
Begin Period Cash Flow
+ 0.97
Stock Based Compensation
Change To Inventory
+ 0.96
End Period Cash Flow
Change To Netincome
+ 0.95
Stock Based Compensation
Change To Inventory
+ 0.95
Stock Based Compensation

High Negative Relationship

Change Receivables
- 0.99
Cash Flows Other Operating
Investments
- 0.98
Depreciation
Change To Inventory
- 0.97
Net Borrowings
Change Receivables
- 0.96
Cash And Cash Equivalents Changes
Change To Netincome
- 0.96
Net Borrowings
Cash And Cash Equivalents Changes
- 0.95
Change To Operating Activities

Immunovant cash flow statement Accounts

202020212022202320242025 (projected)
Change In Cash93.6M299.6M93.7M(117.3M)258.8M78.6M
Stock Based Compensation18.8M34.2M32.3M41.1M49.5M25.6M
Free Cash Flow(83.5M)(106.4M)(188.4M)(214.6M)(376.6M)(357.8M)
Change In Working Capital4.6M15.1M(10.9M)2.6M(12.0M)(11.4M)
Total Cashflows From Investing Activities(210K)(254K)(197K)(360K)(759K)(721.1K)
Other Cashflows From Financing Activities383.1M200.1M385K(318K)4.5M4.3M
Depreciation65K126K193K231K377K395.9K
Other Non Cash Items933K1.1M1.1M1.1M133K126.4K
Capital Expenditures31K210K254K197K360K759K
Total Cash From Operating Activities(83.3M)(106.1M)(188.2M)(214.2M)(375.9M)(357.1M)
Change To Operating Activities(474K)3.8M3.8M10.6M12.2M12.8M
Net Income(66.4M)(107.4M)(156.7M)(211.0M)(259.3M)(413.8M)
Total Cash From Financing Activities147.0M383.1M200.1M70.9M472.4M454.5M
Change To Netincome6.6M18.5M34.2M32.3M37.1M39.0M
Change To Liabilities967K5.7M25.9M(1.4M)(1.6M)(1.5M)
Sale Purchase Of Stock1K385.2M200M70.9M28.8K27.3K
End Period Cash Flow400.1M493.8M376.5M635.4M714.0M428.6M
Investments(210K)(254K)(197K)(360K)(759K)(721.1K)
Begin Period Cash Flow100.6M400.1M493.8M376.5M635.4M369.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Immunovant Stock Analysis

When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY